Beta blockers have been shown to prolong survival in chronic heart failure. It is currently a matter of debate whether any β blocker is superior to the other in terms of improving symptoms, left ...

The clinical benefit of β blockade has been proven in a variety of pathologic settings, including hypertension, angina pectoris, acute- and post-myocardial infarction, and congestive heart failure.

Specifically, the research shows that women who take beta-blockers—a type of medicine often used to control high blood ...

In addition newer drugs like SGLT2 inhibitors, Angiotensin receptor neprisilyn inhibitors ,beta, blockers ,mineralocorticoid ...

Bisoprolol is reaffirmed as a key cardioselective Beta-1-blocker across the cardiovascular disease (CVD) continuum, with a ...

In this high-yield, clinically focused session, Dr. Steven L. Cohn, one of the leading experts in perioperative medicine, ...

Over the past 50 years, overall heart disease death rates have dropped by 66% and deaths from heart attacks have declined by ...

The last 50 years have seen enormous strides made in public awareness of things like CPR, the signs of a heart attack, and lifestyle factors that can increase the risk of a heart attack, while ...

Heart failure is a serious health problem in the United States, affecting millions of people and placing a heavy burden on ...

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

For patients with atrial fibrillation, catheter ablation reduces the risks for ischemic stroke at more than 30 days, mortality, and HF hospitalization.